0001209191-24-000425.txt : 20240103
0001209191-24-000425.hdr.sgml : 20240103
20240103164744
ACCESSION NUMBER: 0001209191-24-000425
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Balthaser Kevin
CENTRAL INDEX KEY: 0001957554
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37581
FILM NUMBER: 24507540
MAIL ADDRESS:
STREET 1: C/O ACLARIS THERAPEUTICS, INC.
STREET 2: 701 LEE ROAD, SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aclaris Therapeutics, Inc.
CENTRAL INDEX KEY: 0001557746
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 460571712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 701 LEE ROAD
STREET 2: SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
BUSINESS PHONE: 484-324-7933
MAIL ADDRESS:
STREET 1: 701 LEE ROAD
STREET 2: SUITE 103
CITY: WAYNE
STATE: PA
ZIP: 19087
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-01
0
0001557746
Aclaris Therapeutics, Inc.
ACRS
0001957554
Balthaser Kevin
C/O ACLARIS THERAPEUTICS, INC.
701 LEE ROAD, SUITE 103
WAYNE
PA
19087
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-01-01
4
M
0
7500
A
22961
D
Common Stock
2024-01-01
4
F
0
2536
1.05
D
20425
D
Restricted Stock Units
2024-01-01
4
M
0
7500
0.00
D
Common Stock
7500
22500
D
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
On February 1, 2023, the Reporting Person was granted 30,000 restricted stock units. The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of January 1, 2023, subject to the Continuous Service of the Reporting Person (as defined in the Plan) as of each such date.
/s/ Mark Ballantyne, Attorney-in-Fact
2024-01-03